Portal de Periódicos da CAPES

The development of pulmonary embolus in patients with haemophilia A and high‐titre inhibitors – a case series and review of the literature

2015; Wiley; Volume: 21; Issue: 2 Linguagem: Inglês

10.1111/hae.12600

1365-2516

M. Silvey, Shannon L. Carpenter, Brian M. Wicklund,

Blood Coagulation and Thrombosis Mechanisms

HaemophiliaVolume 21, Issue 2 p. e134-e136 Letter to the Editor The development of pulmonary embolus in patients with haemophilia A and high-titre inhibitors – a case series and review of the literature M. S. Silvey, Corresponding Author M. S. Silvey Department of Pediatrics, Children's Mercy Hospital, Kansas City, MO, USA Correspondence: Michael Silvey, Children's Mercy Hospital, 2401 Gillham Rd., Kansas City, MO 64108, USA. Tel.:+816-302-6808; fax: +816-302-9894; e-mail: [email protected]Search for more papers by this authorS. L. Carpenter, S. L. Carpenter Department of Pediatrics, Children's Mercy Hospital, Kansas City, MO, USASearch for more papers by this authorB. M. Wicklund, B. M. Wicklund Department of Pediatrics, Children's Mercy Hospital, Kansas City, MO, USASearch for more papers by this author M. S. Silvey, Corresponding Author M. S. Silvey Department of Pediatrics, Children's Mercy Hospital, Kansas City, MO, USA Correspondence: Michael Silvey, Children's Mercy Hospital, 2401 Gillham Rd., Kansas City, MO 64108, USA. Tel.:+816-302-6808; fax: +816-302-9894; e-mail: [email protected]Search for more papers by this authorS. L. Carpenter, S. L. Carpenter Department of Pediatrics, Children's Mercy Hospital, Kansas City, MO, USASearch for more papers by this authorB. M. Wicklund, B. M. Wicklund Department of Pediatrics, Children's Mercy Hospital, Kansas City, MO, USASearch for more papers by this author First published: 21 January 2015 https://doi.org/10.1111/hae.12600Citations: 3Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL No abstract is available for this article. References 1Kreuz W, Ettingshausen CE, Auerswald G et al. Epidemiology of inhibitors and current treatment strategies. Haematologica 2003; 88: EREP04 2Leissinger C, Gringeri A, Antmen B et al. Anti-inhibitor coagulant complex prophylaxis in hemophilia with inhibitors. N Engl J Med 2011; 365: 1684– 92. 3Lusher JM, Shapiro SS, Palascak JE. Efficacy of prothrombin complex concentrates in hemophiliacs with antibodies to factor VIII: a multicenter therapeutic trial. N Engl J Med 1980; 303: 421– 5. 4Konkle BA, Ebbesen LS, Erhardtsen E et al. Randomized prospective clinical trial of recombinant factor VIIa for secondary prophylaxis in hemophilia patients with inhibitors. J Thromb Haemost 2007; 5: 1904– 13. 5Astermark J, Donfield SM, DiMichele DM et al. A randomized comparison of bypassing agents in hemophilia complicated by an inhibitor: the FEIBA NovoSeven Comparison (FENOC) Study. Blood 2007; 109: 546– 51. 6Ehrlich HJ, Henzl MJ, Gomperts ED. Safety of factor VIII inhibitor bypass activity (FEIBA): 10-year compilation of thrombotic adverse events. Hemophilia 2002; 8: 83– 90. 7Roberts H. Recombinant factor VIIa (NovoSeven)and the safety of treatment. Semin Hematol 2001; 38: 48– 50. 8Coppola A, Franchini M, Makris M, Santagostino E, Di Minno G, Mannucci PM. Thrombotic adverse events to coagulation factor concentrates for treatment of patients with haemophilia and von Willebrand disease: a systematic review of prospective studies. Haemophilia 2012; 18: e173– 87. 9Hay CRM, DiMichele DM. The principal results of the International Immune Tolerance Study: a randomized dose comparison. Blood 2012; 119: 1335– 44. Citing Literature Volume21, Issue2March 2015Pages e134-e136 ReferencesRelatedInformation